Aug. 18 at 11:01 AM
$KPTI funded until September theyll need to get the price up
– Total Revenue was
$33.4 Million, and U.S. XPOVIO® (selinexor) Net Product Revenue was
$30.8 Million for the Second Quarter of 2026 –
– Company Reaffirms Full-Year 2026 Total Revenue Guidance of
$130 Million to
$150 Million Including U.S. XPOVIO Net Product Revenue Guidance of
$115 Million to
$130 Million –
The Company expects its existing liquidity, including cash, cash equivalents and investments, together with anticipated cash flow from net product revenue and license and other revenue, to fund its current operating plans into September 2026.
https://www.prnewswire.com/news-releases/karyopharm-reports-second-quarter-2026-financial-results-and-highlights-continued-progress-toward-myelofibrosis-snda-submission-302850269.html
